JMP Securities Maintains Market Outperform on ACADIA Pharmaceuticals, Raises Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jason Butler maintains a Market Outperform rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and raises the price target from $39 to $42.
November 03, 2023 | 7:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ACADIA Pharmaceuticals' price target has been raised from $39 to $42 by JMP Securities, maintaining a Market Outperform rating.
The news of JMP Securities raising the price target for ACADIA Pharmaceuticals and maintaining a Market Outperform rating is likely to have a positive impact on the company's stock in the short term. Investors may see this as a sign of confidence in the company's future performance, potentially driving up demand for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100